Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
Open4.220 | Close4.150 |
Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.280 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
RENB | Renovaro Biosciences | 4.42% | 270.7M |
IPHA | Innate Pharma | -4.17% | 203.7M |
INZY | Inozyme Pharma | -0.59% | 259.3M |
IMRX | Immuneering | -1.92% | 224.7M |
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
There is no dividend information for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.